|
CimaVax-EGF is the first therapeutic cancer vaccine developed to target non-small-cell lung carcinoma (NSCLC), the most common form of lung cancer. The vaccine was the result of a 25-year research project at Cuba’s Center of Molecular Immunology.〔 〕〔 〕 The product has gone through 2 trial phases in Cuba and is currently in the process of going through a third trial, and there are agreements in place to test it in the United States (at Roswell Park Cancer Institute, subject to approval of a New Drug Application by the U.S. Food and Drug Administration), Japan, and some European countries.〔 〕 It is currently only available in Cuba. In October 2015 Serbian Institute of Virology Torlak signed memorandum for a full medical treatment of 30 patients that will be part of a clinical study.〔(【引用サイトリンク】title='Cuban anti-cancer vaccines soon to be available in Serbia' )〕 CimaVax is relatively cheap to produce and store, and has low toxicity.〔 Side effects of the vaccine appear to be mild, and include chills, fever, and feeling sick.〔 〕〔 ==Mechanism== CimaVax is an active vaccine in which patients are immunized with epidermal growth factor (EGF), thus raising antibodies targeting EGF itself. The product is also formulated with the ''Neisseria meningitidis'' outer protein P64k and Montanide ISA 51 as an adjuvant to potentiate the immune response.〔 〕 The epidermal growth factor receptor (EGFR) is hijacked by many types of cancer, including cancers of the lung, colon, kidney, and head and neck. By raising antibodies against EGF, which is EGFR's major ligand, the concentrations of EGF in the blood are reduced. Thus CimaVax does not target the cancer cells directly, but is expected to work against these cancers by denying the cancers the growth stimulus they require.〔〔 〕 For this reason, the Roswell Park group thinks that it may prove most useful as a ''preventive'' vaccine rather than as a cancer therapy ''per se''.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「CimaVax-EGF」の詳細全文を読む スポンサード リンク
|